PTGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-05), Protagonist Therapeutics's current share price is $29.31. Protagonist Therapeutics's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was $0.91. Protagonist Therapeutics's Cyclically Adjusted PS Ratio for today is 32.21.
The historical rank and industry rank for Protagonist Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past 10 years, Protagonist Therapeutics's highest Cyclically Adjusted PS Ratio was 35.33. The lowest was 23.95. And the median was 30.80.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Protagonist Therapeutics's adjusted revenue per share data of for the fiscal year that ended in Dec23 was $1.057. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.91 for the trailing ten years ended in Dec23.
The historical data trend for Protagonist Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | 25.25 |
Protagonist Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | 25.25 | - |
For the Biotechnology subindustry, Protagonist Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Protagonist Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 29.31 | / | 0.91 | |
= | 32.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:
For example, Protagonist Therapeutics's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec23 (Change) | * | Current CPI (Dec23) |
= | 1.057 | / | 129.4194 | * | 129.4194 | |
= | 1.057 |
Current CPI (Dec23) = 129.4194.
Protagonist Therapeutics Annual Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201412 | 0.000 | 99.070 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201712 | 1.134 | 104.011 | 1.411 |
201812 | 1.383 | 105.998 | 1.689 |
201912 | 0.009 | 108.420 | 0.011 |
202012 | 0.832 | 109.897 | 0.980 |
202112 | 0.591 | 117.630 | 0.650 |
202212 | 0.542 | 125.222 | 0.560 |
202312 | 1.057 | 129.419 | 1.057 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Protagonist Therapeutics (NAS:PTGX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Protagonist Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Suneel Gupta | officer: Chief Development Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Patel Dinesh V Ph D | director, officer: President and CEO | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Lewis T Williams | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Bryan Giraudo | director | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
Harold E Selick | director | |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Sarah A O'dowd | director | 3185 LAURELVIEW COURT, FREMONT CA 94538 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Asif Ali | officer: Chief Financial Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Donald A. Kalkofen | officer: Chief Financial Officer | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
David Y Liu | officer: Chief Scientific Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Chaitan Phd Khosla | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard S Shame | officer: Chief Medical Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
From GuruFocus
By GuruFocus Research • 11-04-2023
By GuruFocus Research • 12-16-2023
By ACCESSWIRE • 12-12-2023
By ACCESSWIRE • 01-03-2024
By ACCESSWIRE • 08-17-2023
By ACCESSWIRE • 10-04-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire PRNewswire • 05-12-2023
By ACCESSWIRE • 07-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.